Literature DB >> 8698046

DNA sequence analysis of hprt mutations in lymphocytes from Sprague-Dawley rats treated with 7,12-dimethylbenz[a]anthracene.

R H Heflich1, R A Mittelstaedt, M G Manjanatha, L E Lyn-Cook, A Aidoo.   

Abstract

Treatment of female Sprague-Dawley rats with the potent mammary gland carcinogen 7,12-dimethylbenz[a]anthracene (DMBA) results in the formation of DNA adducts with dG and dA and in the induction of 6-thioguanine-resistant (TGr) lymphocyte mutants. In this study, we have examined the types of mutations induced in TGr lymphocytes from DMBA-treated rats. DNA from 263 TGr lymphocyte clones was screened for mutations in exons 2, 3, and 8 of the hprt gene by polymerase chain reaction (PCR) amplification of the exons followed by heteroduplex analysis using denaturing gradient-gel electrophoresis. Twenty-five of the clones produced heteroduplexes in exon 2, 35 produced heteroduplexes in exon 3, and 36 produced heteroduplexes in exon 8. Direct sequence analysis of the heteroduplexes revealed 96 mutations, and at least 74 of these mutations were produced independently. Eighty-five of the total mutations were simple base pair (bp) substitutions, with A --> T and G --> T transversions being the predominant types. Seven mutations were deletions, three were complex bp substitutions, and one was an insertion. The results suggest that the types of mutations produced by DMBA in rat lymphocytes are specific to the DNA adducts produced by this compound.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698046     DOI: 10.1002/(SICI)1098-2280(1996)28:1<5::AID-EM3>3.0.CO;2-G

Source DB:  PubMed          Journal:  Environ Mol Mutagen        ISSN: 0893-6692            Impact factor:   3.216


  1 in total

1.  Carcinogen-induced loss of heterozygosity at the Aprt locus in somatic cells of the mouse.

Authors:  S W Wijnhoven; P P Van Sloun; H J Kool; G Weeda; R Slater; P H Lohman; A A van Zeeland; H Vrieling
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.